Tag: 0001

ORION OYJ
LEHDISTÖTIEDOTE
21.7.2025 klo 10.30

빅토리아, 세이셸, July 21, 2025 (GLOBE NEWSWIRE) --  암호화폐 거래소이자 웹3.0 기업인 Bitget이 현물 거래용 칼데라(ERA)를 상장한다고 발표했다. 칼데라는 수평적 확장과 롤업 간의 상호 운용성을 가능하게 하는 이더리움의 롤업 플랫폼이다. ERA/USDT 쌍의 거래는 2025년 7월 17일 15:30(UTC)에 시작되었으며, 인출은 2025년 7월 18일 16:30(UTC)부터 가능하다.

VICTORIA, Seychelles, July 21, 2025 (GLOBE NEWSWIRE) -- Bitget, bursa mata wang kripto dan syarikat Web3 yang terkemuka, telah mengumumkan penyenaraian Caldera (ERA) untuk dagangan spot. Caldera merupakan platform rollup berasaskan Ethereum yang membolehkan penskalaan mendatar dan interoperabiliti antara rollup. Dagangan pasangan ERA/USDT telah bermula pada 17 Julai 2025, jam 15:30 (UTC) dan pengeluaran tersedia mulai 18 Julai 2025, jam 16:30 (UTC).

VICTORIA, Seychelles, July 20, 2025 (GLOBE NEWSWIRE) -- A Bitget, principal corretora de criptomoedas e empresa Web3, anunciou a listagem da Caldera (ERA) para negociação à vista. Caldera é uma plataforma de rollup no Ethereum que permite escalonamento horizontal e interoperabilidade entre rollups. A negociação do par ERA/USDT começou em 17 de julho de 2025, às 15h30 (UTC), com saques disponíveis a partir de 18 de julho de 2025, às 16h30 (UTC).

VICTORIA, Seychelles, July 20, 2025 (GLOBE NEWSWIRE) -- Bitget, la empresa líder en la bolsa de criptomonedas y Web3, ha anunciado la incorporación de Caldera (ERA) para sus operaciones al contado. Caldera es una plataforma de rollups basada en Ethereum que admite la escalabilidad horizontal y la interoperabilidad entre rollups. Las operaciones con el par ERA/USDT comenzaron el 17 de julio de 2025 a las 15:30 (UTC), y los retiros estarán disponibles a partir del 18 de julio de 2025 a las 16:30 (UTC).

ויקטוריה, איי סיישל, July 20, 2025 (GLOBE NEWSWIRE) --

Bitget, בורסת המטבעות הקריפטוגרפים המובילה וחברת Web3, הודיעה על הרישום של Caldera (ERA) למסחר בספוט. Caldera היא פלטפורמת הכרזה מבוססת Ethereum המאפשרת גידול אופקי ופעילות הדדית בין הכרזות. המסחר בצמד ERA/USDT החל ב-17 ביולי 2025, 15:30 (UTC), עם משיכות שהיו לזמינות החל ב-18 ביולי 2025, 16:30 (UTC).

Half-year liquidity contract statement for JCDECAUX SE 

On 5 February 2025, Pandora announced a new share buyback programme, cf. Company announcement no. 923. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
                                                                                                                                                      
The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes.

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the Company (the “Placement Shares”), at a price of HKD68.60 per share, in the offering by Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”) in an offshore transaction outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”)(the “Offshore Placement”), for aggregate gross proceeds of approximately HKD1,509.2 million (or approximately US$192.3 million based on exchange rate of 1 USD to 7.85 HKD), before deducting placing fees and other offering expenses. The Offshore Placement, which was oversubscribed by eight times, is expected to close on July 17, 2025.

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”), proposes to offer ordinary shares, par value US$0.0001 per share, of the Company (the “Placement Shares”) in an offshore transaction outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors (the “Offshore Placement”). At the time of the closing of the Offshore Placement, the Vendor would subscribe for, and the Company would issue to the Vendor new ordinary shares of the Company (the “Replacement Shares”) at the same number as the number of the Placement Shares offered in the Offshore Placement and at the same price per share as the price per share for the Placement Shares. The closing of the transaction involving the issuance of the Replacement Shares will be subject to customary closing conditions and take place after the closing of the Offshore Placement. In connection with the Offshore Placement, the representatives in the Company’s U.S. initial public offering in January 2025 waived a lock-up restriction with respect to the Placement Shares held by the Vendor.

In week 28 of 2025, Kaldalón hf. purchased 2,544,345 of its own shares for a total consideration of ISK 61,909,963, as detailed below:

Í viku 28 árið 2025 keypti Kaldalón hf. 2.544.345 eigin hluti að kaupvirði kr. 61.909.963 skv. sundurliðun hér á eftir;

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies